Treatments

The following database contains products that have been granted orphan status, or have been market approval in the EU or the USA.

You can filter the content by clicking on the titles: Product, Indication, Sponsor and Date. Clicking once, will filter the column alphabetically from A – Z and a second click on the same title will filter from Z – A.

Become a Partner.

Country Product Indication Sponsor Date
Uridine 5′-triphosphate Cystic fibrosis Inspire Pharmaceuticals, Inc.;4222 Emperor Boulevard, Suite 470;Durham, North Carolina, 27703 December 4, 1995
Interferon gamma-1b Renal cancer Horizon Pharma Ireland Limited;Connaught House, 1st Floor, 1 Burlington Road;Dublin 4 December 4, 1995
Recombinant methionyl human stem cell factor Primary bone marrow failure Amgen, Inc.;One Amgen Center Drive;Thousand Oaks, California, 91320 November 22, 1995
Omega-3 (n-3) polyunsaturated fatty acid with all double bonds in the cis configuration Prevention of organ graft rejection Research Triangle Pharmaceuticals;4364 South Alston Avenue;Durham, North Carolina, 27713 November 22, 1995
Sorivudine Herpes zoster (shingles) in immunocompromised patients Bristol-Myers Squibb;5 Research Parkway, P.O. Box 5100;Wallingford, Connecticut, 06492 November 9, 1995
Etiocholanedione Aplastic anemia aplastic anemia SuperGen, Inc.;4140 Dublin Blvd., Suite 200;Dublin, California, 94568 November 3, 1995
Recombinant human relaxin Systemic scleroderma Connetics Corporation;3400 West Bayshore Road;Palo Alto, California, 94303 November 3, 1995
Lidocaine patch 5% For relief of allodynia (painful hypersensitivity), and chronic pain in postherpetic neuralgia Teikoku Pharma USA, Inc.;745-D Camden Ave.;Campbell, California, 95008 October 24, 1995
Lucinactant Respiratory distress syndrome in premature infants Windtree Therapeutics, Inc.;2600 Kelly Road, Suite 100;Warrington, Pennsylvania, 18976 October 18, 1995
Recombinant human insulin-like growth factor-I Post-poliomyelitis syndrome Teva Branded Pharmaceutical Product R&D;, Inc.;41 Moores Road;Frazer, Pennsylvania, 19355 October 13, 1995
Mycobacterium avium sensitin RS-10 For use in the diagnosis of invasive Mycobacterium avium disease in immunocompetent individuals Statens Seruminstitut;5 Artillerivej, DK-2300 Copenhagen S; October 11, 1995
Elcatonin Intrathecal treatment of intractable pain Innapharma, Inc.;10 Mountainview Road;Upper Saddle River, New Jersey, 07458 September 25, 1995
Porfiromycin Squamous cell carcinoma of head and neck Boehringer Ingelheim Pharmaceuticals, Inc.;900 Ridgebury Road, PO Box 368;Ridgefield, Connecticut, 06877 September 19, 1995
Sterile talc powder Malignant pleural effusion Bryan Corporation;4 Plympton Street;Woburn, Massachusetts, 01801 September 18, 1995
Broxuridine Radiation sensitizer in the treatment of primary brain tumors NeoPharm, Inc.;225 East Deerpath, Suite 250;Lake Forest, Illinois, 60045 September 18, 1995
RGG0853, E1A lipid complex Ovarian cancer Targeted Genetics Corporation;1100 Olive Way, Suite 100;Seattle, Washington, 98101 September 15, 1995
Lamotrigine Lennox-Gastaut syndrome Glaxo Wellcome Research and Development;5 Moore Drive, P.O. Box 13398;Research Triangle Park, North Carolina, 27709 August 23, 1995
Fibrinogen (human) For the control of bleeding and prophylactic treatment of patients deficient in fibrinogen Alpha Therapeutic Corporation;5555 Valley Boulevard;Los Angeles, California, 90032 August 23, 1995
Thalidomide Erythema nodosum leprosum Celgene Corporation;86 Morris Avenue;Summit, New Jersey, 07901 July 26, 1995
Alglucerase injection Replacement therapy in patients with Type II and III Gaucher's disease Genzyme Corporation;One Kendall Square;Cambridge, Massachusetts, 02139 July 21, 1995
Apomorphine The on-off fluctuations associated with late-stage Parkinson's disease Pentech Pharmaceuticals, Inc.;1110 Lake Cook Rd., Suite 257;Buffalo Grove, Illinois, 60089 July 17, 1995
Lucinactant Acute respiratory distress syndrome Windtree Therapeutics, Inc.;2600 Kelly Road, Suite 100;Warrington, Pennsylvania, 18976 July 17, 1995
Filgrastim For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy Amgen, Inc.;1840 Dehavilland Drive;Thousand Oaks, California, 91320 July 17, 1995
Synsorb Pk Verocytotoxogenic E. coli infections. Synsorb Biotech Inc.;201, 1204 Kensington Road, N.W., Calgary, Alberta; July 17, 1995
Mitolactol As adjuvant therapy in the treatment of primary brain tumors Targent, Inc.;155 Lambert Drive;Princeton, New Jersey, 08540 July 12, 1995